Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928399" target="_blank" >RIV/00064173:_____/25:43928399 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/25:10497875 RIV/00216208:11120/25:43928399 RIV/00064165:_____/25:10497875

Result on the web

<a href="https://doi.org/10.1080/14737159.2025.2500659" target="_blank" >https://doi.org/10.1080/14737159.2025.2500659</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14737159.2025.2500659" target="_blank" >10.1080/14737159.2025.2500659</a>

Result language

angličtina

Original language name

Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas

Original language description

INTRODUCTION: Pathogenesis of large B-cell lymphomas (LBCL) and follicular lymphomas (FL) is a multistep process associated with development of diverse DNA alterations and consequent deregulation of critical cellular processes. Detection of tumor-associated mutations within non-tumor compartments (mainly plasma) is the basis of the &apos;liquid biopsy&apos; concept. Apart from tumor mutational profiling, quantitative analysis of circulating tumor DNA (ctDNA) allows longitudinal assessment of tumor burden. ctDNA-based technologies provide a new tool for tumor diagnostics and treatment personalization. AREAS COVERED: Our review provides a comprehensive overview and summary of available ctDNA studies in LBCL and FL. The accuracy of ctDNA based detection of lymphoma associated DNA alterations is correlated to the known LBCL and FL molecular landscape. Additionally, we summarized available evidence that supports and justifies the clinical use of ctDNA for lymphoma risk stratification, treatment response evaluation, and treatment response-adapted therapy. Lastly, we discuss other clinically important ctDNA applications: monitoring of lymphoma clonal evolution within resistance and/or relapse development and utilization of ctDNA for diagnostics in non-blood fluids and compartments (e.g. cerebrospinal fluid in primary CNS lymphomas). EXPERT OPINION: Despite certain challenges including methodological standardization, ctDNA holds promise to soon become an integral part of lymphoma diagnostics and treatment management.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Expert Review of Molecular Diagnostics

ISSN

1473-7159

e-ISSN

1744-8352

Volume of the periodical

25

Issue of the periodical within the volume

6

Country of publishing house

GB - UNITED KINGDOM

Number of pages

21

Pages from-to

275-295

UT code for WoS article

001492944300001

EID of the result in the Scopus database

2-s2.0-105005863273